Amphotericin B Lipid Complex in the Management of Invasive Fungal Infections in Immunocompromised Patients

[1]  J. Mehta,et al.  Best practice guidelines for the management of adverse events associated with amphotericin B lipid complex (Expert Opinion on Drug Safety (2010) 9, 1, (139-147)) , 2011 .

[2]  J. Ito,et al.  Approaches to the early treatment of invasive fungal infection , 2010, Leukemia & lymphoma.

[3]  J. Wingard,et al.  Drug-Induced Nephrotoxicity Caused by Amphotericin B Lipid Complex and Liposomal Amphotericin B: A Review and Meta-Analysis , 2010, Medicine.

[4]  Thomas J Walsh,et al.  Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  Giuseppe Leone,et al.  Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study , 2010, Haematologica.

[6]  J. Mehta,et al.  Best practice guidelines for the management of adverse events associated with amphotericin B lipid complex , 2010, Expert opinion on drug safety.

[7]  S. Sadullah,et al.  The current role of amphotericin B lipid complex in managing systemic fungal infections , 2009, Current medical research and opinion.

[8]  R. Laniado-Laborín,et al.  Amphotericin B: side effects and toxicity. , 2009, Revista iberoamericana de micologia.

[9]  J. Czub,et al.  Amphotericin B and its new derivatives - mode of action. , 2009, Current drug metabolism.

[10]  J. Starý,et al.  Successful therapy with ABLC, surgery and posaconazole for Rhizopus microsporus var. rhizopodiformis liver eumycetoma in a child with acute leukaemia , 2009, Mycoses.

[11]  D. Ambrosino,et al.  Successful treatment of Cryptococcal meningitis with a combination of liposomal amphotericin B, flucytosine and posaconazole: two case reports. , 2009, In vivo.

[12]  N. O'connor,et al.  Prospective audit of the effectiveness of hydrocortisone premedication on drug delivery reactions following amphotericin B lipid complex* , 2009 .

[13]  H. Einsele,et al.  Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology , 2009, Haematologica.

[14]  D. Liew,et al.  Cost-effectiveness evaluation of voriconazole versus liposomal amphotericin B as empirical therapy for febrile neutropenia in Australia. , 2008, The Journal of antimicrobial chemotherapy.

[15]  R. Murray,et al.  Meta‐analysis of nebulized amphotericin B to prevent or treat pulmonary aspergillosis in immunosuppressed animals , 2008, Transplant infectious disease : an official journal of the Transplantation Society.

[16]  I. Odeyemi,et al.  Economic analysis of micafungin versus liposomal amphotericin B for treatment of candidaemia and invasive candidiasis in Germany , 2008, Current medical research and opinion.

[17]  J. Perfect.  Aerosolized antifungal prophylaxis: the winds of change? , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  G. Dinç,et al.  Comparison of the efficacy of combination and monotherapy with caspofungin and liposomal amphotericin B against invasive candidiasis. , 2008, Saudi medical journal.

[19]  W. Hop,et al.  Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  H. Schønheyder,et al.  Semi-national surveillance of fungaemia in Denmark 2004-2006: increasing incidence of fungaemia and numbers of isolates with reduced azole susceptibility. , 2008, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[21]  D. Kontoyiannis,et al.  Amphotericin B lipid complex versus liposomal amphotericin B monotherapy for invasive aspergillosis in patients with hematologic malignancy , 2008, Cancer.

[22]  N. Gow,et al.  One year prospective survey of Candida bloodstream infections in Scotland , 2007, Journal of medical microbiology.

[23]  U. Reichard,et al.  Epidemiology and antifungal susceptibilities of Candida spp. to six antifungal agents: results from a surveillance study on fungaemia in Germany from July 2004 to August 2005. , 2007, The Journal of antimicrobial chemotherapy.

[24]  V. Gant,et al.  A cost-effectiveness analysis of caspofungin vs. liposomal amphotericin B for treatment of suspected fungal infections in the UK , 2007, European journal of haematology.

[25]  D. Paterson,et al.  Variation in antifungal prophylaxis strategies in lung transplantation , 2006, Transplant infectious disease : an official journal of the Transplantation Society.

[26]  T. Walsh,et al.  Compartmentalized Intrapulmonary Pharmacokinetics of Amphotericin B and Its Lipid Formulations , 2006, Antimicrobial Agents and Chemotherapy.

[27]  J. Garbino,et al.  Invasive aspergillosis: is treatment with "inexpensive" amphotericin B cost saving if "expensive" voriconazole is only used on demand? , 2006, Swiss medical weekly.

[28]  R. Grillot,et al.  Candidaemia in Europe: epidemiology and resistance. , 2006, International journal of antimicrobial agents.

[29]  J. Perfect,et al.  Non‐comparative evaluation of the safety of aerosolized amphotericin B lipid complex in patients undergoing allogeneic hematopoietic stem cell transplantation , 2006, Transplant infectious disease : an official journal of the Transplantation Society.

[30]  M. Bassetti,et al.  Epidemiological trends in nosocomial candidemia in intensive care , 2006, BMC infectious diseases.

[31]  J. Ito,et al.  Effectiveness of amphotericin B lipid complex (ABLC) treatment in allogeneic hematopoietic cell transplant (HCT) recipients with invasive aspergillosis (IA) , 2005, Bone Marrow Transplantation.

[32]  P. Flynn,et al.  Newer treatments for fungal infections. , 2005, The journal of supportive oncology.

[33]  B. Alexander,et al.  Study of renal safety in amphotericin B lipid complex-treated patients. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[34]  J. Ito,et al.  Treatment of Candida infections with amphotericin B lipid complex. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[35]  P. Pappas.  Amphotericin B lipid complex in the treatment of invasive fungal infections: results of the Collaborative Exchange of Antifungal Research (CLEAR), an industry-supported patient registry. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[36]  J. Perfect.  Treatment of non-Aspergillus moulds in immunocompromised patients, with amphotericin B lipid complex. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[37]  J. Ito,et al.  Amphotericin B lipid complex in the management of invasive aspergillosis in immunocompromised patients. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[38]  Russell E. Lewis,et al.  Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. , 2005, The Journal of infectious diseases.

[39]  T. Walsh,et al.  Efficacy and Safety of Amphotericin B Lipid Complex in 548 Children and Adolescents With Invasive Fungal Infections , 2005, The Pediatric infectious disease journal.

[40]  J. Aguado,et al.  Assessment of nephrotoxicity in patients receiving amphotericin B lipid complex: a pharmacosurveillance study in Spain. , 2004, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[41]  J. Sierra,et al.  Low‐dose amphotericin b lipid complex vs. conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies – a randomized, controlled trial , 2004, European journal of haematology.

[42]  O. Faure,et al.  Epidemiology of Candidaemia in Europe: Results of 28-Month European Confederation of Medical Mycology (ECMM) Hospital-Based Surveillance Study , 2004, European Journal of Clinical Microbiology and Infectious Diseases.

[43]  E. Anaissie,et al.  Lipid formulations of amphotericin B preserve and stabilize renal function in HSCT recipients , 2004, Bone Marrow Transplantation.

[44]  R. Martino.  Efficacy, safety and cost-effectiveness of Amphotericin B Lipid Complex (ABLC): a review of the literature , 2004, Current medical research and opinion.

[45]  H. Kantarjian,et al.  Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy , 2004, Cancer.

[46]  J. Perfect,et al.  Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients , 2004, Transplantation.

[47]  D. Golenbock,et al.  The Antifungal Drug Amphotericin B Promotes Inflammatory Cytokine Release by a Toll-like Receptor- and CD14-dependent Mechanism* , 2003, Journal of Biological Chemistry.

[48]  D. Mannino,et al.  The epidemiology of sepsis in the United States from 1979 through 2000. , 2003, The New England journal of medicine.

[49]  T. Walsh,et al.  Plasma Protein Binding of Amphotericin B and Pharmacokinetics of Bound versus Unbound Amphotericin B after Administration of Intravenous Liposomal Amphotericin B (AmBisome) and Amphotericin B Deoxycholate , 2002, Antimicrobial Agents and Chemotherapy.

[50]  G. Maschmeyer.  New antifungal agents-treatment standards are beginning to grow old. , 2002, The Journal of antimicrobial chemotherapy.

[51]  K. Garey,et al.  A Prospective and Retrospective Analysis of the Nephrotoxicity and Efficacy of Lipid‐Based Amphotericin B Formulations , 2001, Pharmacotherapy.

[52]  G. Leverger,et al.  Efficacy of Amphotericin B Lipid Complex in the Treatment of Invasive Fungal Infections in Immunosuppressed Paediatric Patients , 2001, European Journal of Clinical Microbiology and Infectious Diseases.

[53]  V. Fanos,et al.  Renal Transport of Antibiotics and Nephrotoxicity: a Review , 2001, Journal of chemotherapy.

[54]  H. Kantarjian,et al.  Comparison of Amphotericin B Lipid Complex (ABLC) vs. AmBisome in the Treatment of Suspected or Documented Fungal Infections in Patients with Leukemia , 2001, Leukemia & lymphoma.

[55]  E. Anaissie,et al.  A Randomized, Double-Blind Comparative Trial Evaluating the Safety of Liposomal Amphotericin B versus Amphotericin B Lipid Complex in the Empirical Treatment of Febrile Neutropenia , 2000 .

[56]  P. Linden,et al.  Efficacy and safety of Amphotericin B Lipid Complex Injection (ABLC) in solid‐organ transplant recipients with invasive fungal infections , 2000 .

[57]  R. Pizov,et al.  Pulmonary extraction and accumulation of lipid formulations of amphotericin B , 2000, Critical care medicine.

[58]  M. Ghannoum,et al.  A Head-on Comparison of the In Vitro Antifungal Activity of Conventional and Lipid-based Amphotericin B: a Multicenter Study , 2000, Journal of chemotherapy.

[59]  S. Chanock,et al.  Amphotericin B lipid complex in pediatric patients with invasive fungal infections. , 1999, The Pediatric infectious disease journal.

[60]  Chopra,et al.  A comparative analysis of lipid‐complexed and liposomal amphotericin B preparations in haematological oncology , 1998, British journal of haematology.

[61]  B. Guglielmo,et al.  Lipid formulations of amphotericin B: clinical efficacy and toxicities. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[62]  J. Ojwang,et al.  Comparison of In Vitro Antifungal Activities of Free and Liposome-Encapsulated Nystatin with Those of Four Amphotericin B Formulations , 1998, Antimicrobial Agents and Chemotherapy.

[63]  E. Anaissie,et al.  Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[64]  R. Branch,et al.  Pharmacokinetic profile of ABELCET (amphotericin B lipid complex injection): combined experience from phase I and phase II studies , 1997, Antimicrobial agents and chemotherapy.

[65]  S. Singhal,et al.  Amphotericin B lipid complex (ABLC) for the treatment of confirmed or presumed fungal infections in immunocompromised patients with hematologic malignancies , 1997, Bone Marrow Transplantation.

[66]  A. Janoff,et al.  Behavior of amphotericin B lipid complex in plasma in vitro and in the circulation of rats , 1997, Antimicrobial agents and chemotherapy.

[67]  J. Wingard.  Efficacy of amphotericin B lipid complex injection (ABLC) in bone marrow transplant recipients with life-threatening systemic mycoses , 1997, Bone Marrow Transplantation.

[68]  P. Legrand,et al.  Comparative internalization and recycling of different amphotericin B formulations by a macrophage-like cell line. , 1996, The Journal of antimicrobial chemotherapy.

[69]  G. Maschmeyer,et al.  Invasive Aspergillosis , 2012, Drugs.

[70]  P. Williams,et al.  Pharmacoeconomic Analysis of Amphotericin B Lipid Complex versus Liposomal Amphotericin B in the Treatment of Fungal Infections , 2012, PharmacoEconomics.

[71]  J. Stevenson,et al.  Pharmacoeconomic Analysis of Liposomal Amphotericin B versus Voriconazole for Empirical Treatment of Febrile Neutropenia , 2007, Clinical drug investigation.

[72]  L. Pagano,et al.  Design and Methods , 2022 .

[73]  J. Montero,et al.  Efficacy and safety of amphotericin B lipid complex for zygomycosis , 2003 .